Patient Centricity & Collaboration World Congress -

6th Patient Centricity & Collaboration World Congress 2024 Americas

Patient empowerment and understanding to inspire and create a meaningful impact

00Days
00Hours
00Minutes
00Seconds

Patient meets Innovation & Collaboration

Understanding the Patient Journey, enabling a more Patient-Centric Approach.

Introduction
Insight
Who Should Attend

Facilitate Live is proud to welcome you to the upcoming 6th Patient Centricity and Collaboration World Congress 2024 Americas.

The two-day Congress aims to build meaningful collaborations within the industry, advocacy groups, clinicians, researchers, and most importantly, patients and their caregivers. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts in achieving this goal.

Patient-centricity is a vital aspect in the research and development of biopharmaceutical products, disease management, designing a treatment, clinical trial or other health solution. In order to create a patient centric solution, one must truly embrace a collaborative endeavour with the patient and their caregivers. Establishing a patient-centric solution involves getting feedback from real patients and their loved ones, and making decisions based on their medical conditions, experiences, needs, perspectives and priorities.

In the current climate where the patients are increasingly becoming more empowered, life sciences and pharmaceutical companies should confront the status quo and welcome the opportunities to embrace a wide range of patient-centred perspectives presented by an emerging ecosystem. While the technology-driven world poses challenges, it also holds opportunities to build a positive patient experience by coordinating the health ecosystem to centre on the patient. Reevaluating how it develops and delivers drugs to improve experiences and outcomes and also to continuously adapt and transform to meet the evolving needs of patients.

The industry has come a long way with utilising a patient-centred approach. The concept has gone from a buzzword to a potential trend, to a perceivable goal. Whilst the industry has advanced in recent years, the evolving healthcare model and ecosystem brought forward by advances in technology and more involved, empowered patients, means true patient centricity is a continuing quest and a compelling commitment.

We look forward to meeting you at the Congress!

GAIN LATEST INSIGHTS ON:

What does patient centricity mean for the pharmaceutical and life science industry?
Why does the industry need to be a part of the patient-centric movement?
Patient-centric initiatives that have a tremendous impact
Successful strategies and best practices to successfully manage patient-centricity in healthcare
How to develop and execute a strategy to improve patient engagement?
Benefits of patient engagement in drug development and discovery process
Evolving challenges and key considerations inthe ethical and compliant use of relevant data
The potential value of providing access to relevant data to all stakeholders
How to maintain mutually beneficial ongoing partnerships between the patients and industry?
Overcoming myriad challenges to make the clinical trial and drug development process more patient-centred or patient-focused
Setting the pace and expectations thru collaborations
Role of researchers in bridging the communication gap between life science industry and the patient it serves
How to achieve a deeper understanding of the patient experience in the real world.
Practical ways in putting the patient at thecentre of a powerful brand

WHO SHOULD ATTEND?

This Congress is beneficial to patients, pharmaceutical, biotech companies, researchers, physicians, patient advocacy groups, regulatory agencies, technology, and healthcare companies.

Network with representatives involved in the following areas:

Head of Patient Engagement
Patient Services
Engagement Strategy
R&D Patient Engagement
Medical Affairs
Regulatory Affairs and Policy
Patient Support and Patient Engagement
RWE, and Data Management
Quality and Compliance
Clinical Development
Programme Management
Supply Chain Management
Patient Access
Clinical Research
Global Head, Digital Accelerator
Patient Engagement & Portfolio Strategy
Patient Support Strategy & Insights
Patient Experience

Medical Affairs, Global Patient Advocacy & Alliances
Government Policy and Advocacy
Digital Patient Experience Lead
Clinical Operations
Clinical Insights and Experience
Head of Strategy, Access Services
Vice President, Site Collaborations and Patient Centricity
Head of Neuroscience
And much more...

speakers

0 +

days Congress

Presentation

0 +

Attendees

0 +

Key Industry Expert Speakers

2023 / 2024 Speaking Faculty

Comfirmed speakers Apply to speak

Schedule

Content Rich Program Agenda! Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

Day 1 30/10/2024
Day 2 31/10/2024

Auditorium 1

08:00 am - WELCOME COFFEE & REGISTRATION

09:00 am - CHAIRPERSON’S OPENING REMARKS

TRENDS & STRATEGIES IN INTEGRATING PATIENT VOICE

09:10 am - OPENING KEYNOTE PANEL: Realizing the importance of patient needs and engagement in improving patient outcomes?

The value of engaging and communicating with the patient in every part of the clinical research process
Examining the right approach for patient and industry to positively impact healthcare costs and patient outcomes
through patient engagement
How can patient expertise create significant value to the industry?
What are the best practices and strategies to guarantee that patient centricity is at the forefront of pharma?

Moderator:

Panelist:

09:50 am - PLENARY SESSION: Walk the Talk – Transforming from a Product Centric to Patient Centric Company….Best Practices and Learnings

Many biotech/pharmaceutical companies are talking about ”Patient Centricity”, but how can a company actually operate
in a patient-centric way to create meaningful value?
Learn best practices to transition from being product centered to patient centered
Discuss strategies to embed patient centricity throughout your organization.

10:20 am - PLENARY KEYNOTE: Putting patients at the core of your company

Patient Centricity requires new mindsets, relationships – and structures, company-wide.
No stage of development, from discovery through delivery, gets a pass.
No company function continues as before.
Company culture changes, too.
This isn’t easy but the results are worth the journey: to improve outcomes for patients and business performance alike.
If Patient Centricity is a fad, then it’s a failure. It should be the new way of doing business.

10:50 am - MORNING NETWORKING BREAK

11:30 am - SPONSORED SPOTLIGHT: When the tables turn on Patient Community and Pharma collaboration.

Sharing insights into a live real-world example of this type of partnership
Explaining the roles and responsibilities in achieving a positive outcome
Providing key learning to the evolving process
Supplying the audience with guiding principles for future partnerships

12:00 pm - SPONSORED SPOTLIGHT: New Advanced Technologies to Drive Speed in Clinical Trial Design

Learn about the latest technologies that can improve the efficiency and effectiveness of clinical trial design, addressing issues like increasing complexity
Discover the principles and best practices for clinical trial design that can increase the likelihood of success, through a combination of literature analysis and practical experience
Examine the challenges faced by patients during clinical trials and learn about potential solutions that can reduce the burden and increase the benefits for patients

12:30 pm - SPONSORED SPOTLIGHT: Targeting Patient Centricity for Maximum Impact

Understand where patient centricity can advance the interests shared by industry and the patient community
Consider how focused goals and programs can strengthen research and development, commercialization and access
Focus on opportunities to integrate patients, caregivers, consumers and advocates’ key concerns and insights into company plans and decision making
Discuss applications of this targeted approach to your patient centricity goals and programs

1:00 pm - NETWORKING LUNCH - Exhibit Hall

TOPIC FOCUSED STREAM

ACCESS & COLLABORATIONS

2:00 pm - SESSION CHAIR OPENING REMARKS

2:05 pm - Utilizing Trust to Scale Patient-Centric Ecosystems

Health Systems sharing clinical data to advance science
Patient Advocacy Group’s use of multi-stakeholder
registries
21st Century Cures Act enabling patients to have access to
all their clinical data and agency to license
Combined with emerging trusted data market approaches
Creates the opportunity for patient-centric ecosystems at
scale to accelerate discovery -> clinical adoption

2:35 pm - Collaboration: Building access for CBOs and CBAs across the health sector to improve access to clinical trials information.

Learning: Balancing health system priorities and resources to address patient community needs.
Creating policy to end disparities and open access to new regenerative and translational therapies.
Increasing funding and technical support to CBOs for community outreach and education efforts.

3:05 pm - Listen, Listen, Listen, Using the Patient Voice in Care Collaboration.

Financial Toxicity During Breast Cancer Treatment: A Qualitative Analysis to Inform Strategies for Mitigation

3:35 pm - AFTERNOON NETWORKING BREAK

4:15 pm - Practical ways in putting the patient at the centre of a powerful brand

Have patient “Advisors” on a panel for clinical trials.
Have a patient advocate/liaison collaborating.
Patient Surveys

4:45 pm - Bridging the Gap Between Government, Pharmaceutical and Patients on clinical trials and research from a Patient's perspective

Education of the process of clinical trials
Listen to the Patient needs and help them to understand what the focus of the trial is.
Understanding Pharmaceutical costs of trials and research
Dealing with an illness with multiple organ involvement.
Rare Disease

5:15 pm - Patient v. Consumer: DTC Is The New Patient Engagement

How we might innovate our way out of increasing erosion of trust between patients and “the system”, by learning from CPG use cases, nonprofit communications, digital health solutions, shifting trends in consumer media consumption, shared accountability, and increased federal protections.

5:45 pm - CHAIRPERSON’S CLOSING REMARKS

RESEARCH & DEVELOPMENT

2:00 pm - SESSION CHAIR OPENING REMARKS

2:05 pm - Involving patient in streamlining trial operations

Integration of the patient perspective into the development process
Challenges and strategies for improving study protocols
Streamline your clinical trial process to drive enrollment

2:35 pm - Case Study: “Creating and Designing Meaningful Patient-Centered Translational Research

Patients and caregivers know best when it means improving the quality of life.
Reality is much different than theory.
Benefits of real-world experience inserted in basic science equals endpoints and outcomes that can be overlooked as unimportant.

3:05 pm - Patient-Generated Data: The new currency of collaboration.

Across the spectrum of disease, from common to rare, patient data is becoming a critical driver of drug discovery, development, diagnosis,
commercialization and inclusive and equitable access to trials and treatments.

3:35 pm - AFTERNOON NETWORKING BREAK

4:15 pm - Path to Success: Benefits of Collaborating Fully with Patient Advocacy Groups in Trial Development

Contributions that advocacy groups can make to clinical trial development
The importance of knowing the people, their disease, and its burdens
Successful collaborations are a win for all

4:45 pm- The evolution of Patient Centric Drug Product Design within the Pharmaceutical Industry

Patient perception and usability of drug products is critical for efficacy of prescribed treatments.
Drug products should be designed to meet the specific needs of the target patient populations.
A patient centric drug product design approach is critical to support optimal therapeutic outcomes for drug products.
Roll out of digital technology will support the implementation of a patient centric mindset for drug product design.
Case-studies for drug products developed via patient centric drug product design

5:15 pm - Patient-Generated Data: The new currency of collaboration.

Across the spectrum of disease, from common to rare, patient data is becoming a critical driver of drug discovery, development, diagnosis, commercialization and inclusive and equitable access to trials and treatments.

5:45 pm - CHAIRPERSON’S CLOSING REMARKS

Auditorium 1

8:30 am - WELCOME COFFEE & REGISTRATION

9:00 am - CHAIRPERSON’S OPENING REMARKS

CHALLENGES & POTENTIALS OF PATIENT ENGAGEMENT

9:10 am - KEYNOTE PANEL: Increasing inclusion, diversity and equity in clinical research: Breaking down barriers to access

Why diversity and inclusion in clinical trials are crucial?
Understanding critical barriers to minority and underserved patient communities participation in clinical trials
Equity and Inclusion of Rare Disease Patients – A Must on Many Levels
What can the industry do to promote more diversity in the future?
Latest guidelines that make healthcare more inclusive

Moderator:

Panelists:

9:50 am - PLENARY SESSION: Patient safety: Why are we so scared to talk about it?

How knowledge can reduce the fear of Pharma and ultimately save lives.
What do we really know about patient safety, both as an industry and an individual and what are the challenges we face?
How can technology play a role in ensuring patient safety, compliance and pharmacovigilance?
How we can leverage individual and collective data to ensure proper care and Quality of life while reducing damage, saving time and money.

10:20 am - KEYNOTE PRESENTATION: FDA's Patient engagement initiatives

Patient engagement activities incorporating robust and meaningful patient engagement experiences to inform
regulatory work
Considerations in patient engagement
Resources to help engage with FDA

10:50 am - MORNING NETWORKING BREAK

11:30 am - PLENARY SESSION: Industry’s commitment to patient education and access to care

Support different learning styles to ensure patients have equal access to education
Patient centricity for better health outcomes
How to determine cultural nuances and understandings to care

12:00 pm - CASE STUDY: Overcoming barriers and improving circumstantial awareness in clinical trials using real-world patient experience

The importance of data democratization
Common challenges in clinical data review that hinders clinical trials
Strategies in overcoming these challenges
How to seamlessly integrate data from a variety of sources?
How to improve safety review efficiencies and reduce the timeline to critical studies?

12:30 pm - SPOTLIGHT PRESENTATION: Designing an end-to-end patient-centric supply chain for cell and gene therapies

Understanding complexities and addressing challenges faced by the industry in setting up end-to end supply chain for cell and gene therapies
Best practices and lessons learned that guarantees effective manufacturing and delivery of CGTs to the patients who needs them the most
Robust technologies and innovative platforms that connects therapies with patients both in clinical and commercial scale

1:00 pm - NETWORKING LUNCH

2:00 pm - PLENARY SESSION: Advancing Health Equity Through People- and Patient-Centered Engagement

This presentation will highlight how companies can advance health equity through people- and patient- centered frameworks. Learning objectives include:

Specific domains of action for addressing health equity through people and patient engagement;
Success measures of efforts to advance health equity;

2:30 pm - PLENARY SESSION: The art of decision making- lessons learnt and reflection.

Different interpretations of decision making across stakeholders
Value on patient outcomes and engagement (case studies)
Introduce the working model of decision making.

3:00 pm - PLENARY SESSION: Successful strategies and best practices to successfully manage patient-centricity in healthcare

Putting the patient first achieves the best experience and outcome for that person and their family
Improve communication from staff shift-changes in a hospital to getting the patient discharged faster
Setting expectations soon
Updating goals and outcomes; timely

3:30 pm - AFTERNOON NETWORKING BREAK

4:00 pm - PANEL DISCUSSION: The evolution of patient-centred drug development

Recognising key areas to ensure patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation.
Patient’s input to improve quality, relevance, safety and efficacy of drug development
Challenges and opportunities for patient-centric product design
The role of respective stakeholders and the way they interact, from the early steps of drug development to access inreal life?

Moderator:

Panelists:

4:40 pm - CLOSING PANEL DISCUSSION: Driving patient-centric healthcare: the new frontier

Understanding the drivers for innovation in pharma
Partnering with patients and placing patient well-being at the core of all initiatives
Real-world data and patient-reported outcomes presents the power and the potential to redesign healthcare
Innovative approaches for direct-to-patient assume significant importance for driving patient-centricity
Technologies that enhance the patient-centricity in pharma

Moderator:

Panellist:

5:20 pm - CHAIRPERSON’S CLOSING REMARKS

Newsletter Sign Up

No Spam - You will only receive relevant information on Patient Centricity & Collaboration, and event updates

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.

Salvador Berrios

ERP/ CRM / Product Configurator Manager

The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations

Thomas Martin

Associate Vice President, VCGA - Quintiles

I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.